1. Clinical relevance of immunogenicity of biologics in psoriasis: Implications for treatment strategies. (20th May 2014) Authors: Carrascosa, J.‐M.; van Doorn, M.B.A.; Lahfa, M.; Nestle, F.O.; Jullien, D.; Prinz, J.C. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 28:Number 11(2014:Nov.) Page Start: 1424 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Inadvertent pregnancy during ustekinumab therapy in a patient with plaque psoriasis and impetigo herpetiformis. (21st November 2014) Authors: Alsenaid, A.; Prinz, J.C. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 30:Number 3(2016:Mar.) Page Start: 488 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Lesional activation of Tc17 cells in Behçet disease and psoriasis supports HLA class I‐mediated autoimmune responses. (1st December 2021) Authors: Vural, S.; Kerl, K.; Ertop Doğan, P.; Vollmer, S.; Puchta, U.; He, M.; Arakawa, Y.; Heper, A.O.; Karal‐Öktem, A.; Hartmann, D.; Boyvat, A.; Prinz, J.C.; Arakawa, A. Journal: British journal of dermatology Issue: Volume 185:Number 6(2021) Page Start: 1209 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Lesional activation of Tc17 cells in Behçet disease and psoriasis supports HLA class I‐mediated autoimmune responses. (20th September 2021) Authors: Vural, S.; Kerl, K.; Ertop Doğan, P.; Vollmer, S.; Puchta, U.; He, M.; Arakawa, Y.; Heper, A.O.; Karal‐Öktem, A.; Hartmann, D.; Boyvat, A.; Prinz, J.C.; Arakawa, A. Journal: British journal of dermatology Issue: Volume 185:Number 6(2021) Page Start: 1209 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Long‐term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate‐to‐severe psoriasis: results from the PHOENIX 2 study through 5 years of follow‐up. (1st May 2015) Authors: Langley, R.G.; Lebwohl, M.; Krueger, G.G.; Szapary, P.O.; Wasfi, Y.; Chan, D.; Hsu, M.C.; You, Y.; Poulin, Y.; Korman, N.; Prinz, J.C.; Reich, K. Journal: British journal of dermatology Issue: Volume 172:Number 5(2015:May) Page Start: 1371 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Long‐term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate‐to‐severe psoriasis: results from the PHOENIX 2 study through 5 years of follow‐up. (22nd March 2015) Authors: Langley, R.G.; Lebwohl, M.; Krueger, G.G.; Szapary, P.O.; Wasfi, Y.; Chan, D.; Hsu, M.C.; You, Y.; Poulin, Y.; Korman, N.; Prinz, J.C.; Reich, K.; the PHOENIX 2 Investigators Journal: British journal of dermatology Issue: Volume 172:Number 5(2015:May) Page Start: 1371 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. SAT0294 Monitoring disease activity in early psoriatic arthritis with ultrasound - comparison of clinical responders and nonresponders. (23rd January 2014) Authors: Nigg, A.P.; Malchus, A.M.; Grünke, M.; Witt, M.; Prinz, J.C.; Schulze-Koops, H. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 571 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Secukinumab administration by pre‐filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). (11th December 2014) Authors: Blauvelt, A.; Prinz, J.C.; Gottlieb, A.B.; Kingo, K.; Sofen, H.; Ruer‐Mulard, M.; Singh, V.; Pathan, R.; Papavassilis, C.; Cooper, S.; the FEATURE Study Group Journal: British journal of dermatology Issue: Volume 172:Number 2(2015:Feb.) Page Start: 484 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Secukinumab administration by pre‐filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). (1st February 2015) Authors: Blauvelt, A.; Prinz, J.C.; Gottlieb, A.B.; Kingo, K.; Sofen, H.; Ruer‐Mulard, M.; Singh, V.; Pathan, R.; Papavassilis, C.; Cooper, S. Journal: British journal of dermatology Issue: Volume 172:Number 2(2015:Feb.) Page Start: 484 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. The genetic basis for most patients with pustular skin disease remains elusive. (1st March 2018) Authors: Mössner, R.; Wilsmann‐Theis, D.; Oji, V.; Gkogkolou, P.; Löhr, S.; Schulz, P.; Körber, A.; Prinz, J.C.; Renner, R.; Schäkel, K.; Vogelsang, L.; Peters, K.‐P.; Philipp, S.; Reich, K.; Ständer, H.; Jacobi, A.; Weyergraf, A.; Kingo, K.; Kõks, S.; Gerdes, S. Journal: British journal of dermatology Issue: Volume 178:Number 3(2018) Page Start: 740 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗